Skip to content
Menu
Home
About
ABOUT FIREBRICK
HISTORY
OUR VALUES
OUR TEAM
News
Investors
Partners
Contact
News
14 Nov 2022
Nasodine composition patent accepted in Australia
Read More
2 Nov 2022
Update on Nasodine Phase 3 trial
Read More
25 Oct 2022
Nasodine patent granted in Singapore
Read More
14 Sep 2022
Firebrick announces formation of Scientific Advisory Board
Read More
25 May 2022
Nasodine now patented in 26 countries
Read More
25 May 2022
Firebrick appoints Dr Richard Treagus as director
Read More
17 May 2022
Channel 7 shines a spotlight on Firebrick’s Phase 3 common cold trial for Nasodine
Read More
4 May 2022
Peter Molloy discusses the common cold trial on global finance platform Grafa
Read More
3 May 2022
Nasodine Phase 3 common cold trial underway
Read More
26 Apr 2022
Nasodine trial in COVID-19 started
Read More
1 Mar 2022
Firebrick to file appeal seeking immediate approval of Nasodine
Read More
17 Feb 2022
US Patent Granted for Nasodine in COVID-19
Read More
10 Feb 2022
Peter Molloy on the Nasodine SARS-CoV-2 data and the Firebrick vision
Read More
10 Feb 2022
Nasodine in vitro and pilot human COVID-19 studies published
Read More
3 Feb 2022
Peter Molloy on Firebrick’s successful ASX debut and plans for Nasodine
Read More
1 Feb 2022
South African trial of Nasodine in COVID-19 receives local approval to proceed
Read More
28 Jan 2022
Firebrick launch on ASX receives national media attention
Read More
27 Jan 2022
Firebrick Pharma to debut on the ASX
Read More
MENU
Home
About
ABOUT FIREBRICK
HISTORY
OUR VALUES
OUR TEAM
News
Investors
Partners
Contact
